Your browser is no longer supported. Please, upgrade your browser.
APTX Aptinyx Inc. daily Stock Chart
APTX [NASD]
Aptinyx Inc.
Index- P/E- EPS (ttm)-1.72 Insider Own1.30% Shs Outstand45.10M Perf Week-5.45%
Market Cap156.50M Forward P/E- EPS next Y-1.86 Insider Trans- Shs Float37.63M Perf Month-2.53%
Income-57.70M PEG- EPS next Q-0.56 Inst Own45.30% Short Float0.53% Perf Quarter2.06%
Sales3.80M P/S41.18 EPS this Y-62.10% Inst Trans-0.43% Short Ratio0.66 Perf Half Y6.12%
Book/sh3.36 P/B1.03 EPS next Y2.60% ROA-42.20% Target Price11.00 Perf Year-39.12%
Cash/sh2.53 P/C1.37 EPS next 5Y- ROE-44.20% 52W Range2.61 - 6.00 Perf YTD1.46%
Dividend- P/FCF- EPS past 5Y- ROI-36.80% 52W High-40.83% Beta-
Dividend %- Quick Ratio16.80 Sales past 5Y- Gross Margin- 52W Low36.02% ATR0.38
Employees63 Current Ratio16.80 Sales Q/Q0.00% Oper. Margin- RSI (14)42.27 Volatility6.59% 11.13%
OptionableNo Debt/Eq0.00 EPS Q/Q-3.00% Profit Margin- Rel Volume0.40 Prev Close3.47
ShortableYes LT Debt/Eq0.00 EarningsMar 19 AMC Payout- Avg Volume302.89K Price3.55
Recom2.00 SMA20-12.37% SMA50-7.91% SMA2000.25% Volume121,092 Change2.31%
Sep-12-19Initiated Wedbush Outperform
Aug-13-19Downgrade JP Morgan Neutral → Underweight
Jun-20-19Initiated SVB Leerink Outperform $12
Jan-17-19Downgrade JP Morgan Overweight → Neutral
Nov-15-18Initiated Cantor Fitzgerald Overweight $40
Jul-16-18Initiated Leerink Partners Outperform $35
Jul-16-18Initiated JP Morgan Overweight $30
Jan-30-20 07:07AM  Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinsons Disease GlobeNewswire
Jan-18-20 05:09PM  Notable Insider Buys Last Week: Small-Cap Biotechs Benzinga
Jan-17-20 02:11PM  Largest Insider Trades of the Week GuruFocus.com +27.78%
Jan-14-20 04:01PM  Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option GlobeNewswire
Jan-10-20 09:00AM  Aptinyx Announces Pricing of Public Offering of Common Stock GlobeNewswire -10.69%
07:13AM  The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx Benzinga
Jan-09-20 04:08PM  Aptinyx Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-08-20 05:28AM  Did You Manage To Avoid Aptinyx's (NASDAQ:APTX) Devastating 80% Share Price Drop? Simply Wall St.
Dec-16-19 07:18AM  Is Aptinyx Inc. (APTX) A Good Stock To Buy? Insider Monkey
Dec-12-19 07:07AM  Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-09-19 04:05PM  Aptinyx to Present Preclinical Data Exhibiting Effects of NYX-783 in Models of PTSD and Alcohol Use Disorder at the American College of Neuropsychopharmacologys Annual Meeting GlobeNewswire
Dec-05-19 06:58AM  Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinsons Disease GlobeNewswire
Nov-21-19 02:30PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Nov-19-19 09:40PM  SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Nov-18-19 12:45PM  FIRST FIRM TO INVESTIGATE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -5.11%
Nov-15-19 03:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX ACCESSWIRE
Nov-14-19 07:57AM  Aptinyx to Present at Upcoming Investor Conferences GlobeNewswire
Nov-13-19 08:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX ACCESSWIRE
Nov-12-19 05:25PM  Aptinyx Inc. (APTX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM  Aptinyx Reports Third Quarter 2019 Financial Results and Highlights GlobeNewswire
07:27AM  Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions GlobeNewswire
Nov-11-19 08:29PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX GlobeNewswire
Nov-09-19 07:35AM  How Much Of Aptinyx Inc. (NASDAQ:APTX) Do Insiders Own? Simply Wall St.
Nov-05-19 10:32AM  Earnings Preview: Aptinyx Inc. (APTX) Q3 Earnings Expected to Decline Zacks -5.16%
08:07AM  Aptinyx to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 GlobeNewswire
Oct-31-19 07:40PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX ACCESSWIRE
Oct-30-19 09:55AM  FIRST FIRM TO INVESTIGATE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-29-19 01:42PM  EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Aptinyx Inc. GlobeNewswire -6.21%
01:30PM  FIRST FIRM TO INVESTIGATE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
01:07PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aptinyx Inc. - APTX GlobeNewswire
12:30PM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Aptinyx Inc. (APTX) ACCESSWIRE
Oct-28-19 06:27PM  Kaskela Law LLC Announces Investigation of Aptinyx Inc. (APTX) on Behalf of Investors GlobeNewswire
07:57AM  Aptinyx Announces Results of Phase 2 Fibromyalgia Study of NYX-2925 Have Been Selected for Late-Breaking Presentation at the American College of Rheumatology Annual Meeting GlobeNewswire
Oct-25-19 11:15AM  SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-23-19 12:15PM  2018 SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-22-19 05:20PM  INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-18-19 04:45PM  URGENT SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -7.67%
Oct-15-19 02:45PM  FIRST FIRM TO INVESTIGATE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +13.03%
08:46AM  Aptinyx to Present Preclinical Data on Three Clinical-Stage NMDA Receptor Modulators at the 49th Annual Meeting of the Society for Neuroscience GlobeNewswire
Oct-14-19 02:20PM  IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE -8.09%
Oct-11-19 11:30PM  FIRST FIRM TO INVESTIGATE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-10-19 02:55PM  Lifshitz & Miller LLP Announces Investigation of Abeona Therapeutics Inc., Aptinyx Inc., James River Group Holdings, Ltd., The Chemours Company, Overstock.com, Inc., Greenland Acquisition Corporation and Wanda Sports Group Limited PR Newswire
02:00PM  IPO SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-08-19 09:00PM  Aptinyx (APTX) Alert: Johnson Fistel Launches Investigation into Aptinyx Inc.; Investors Suffering Losses Encouraged to Contact Firm PR Newswire
Oct-07-19 08:09PM  IPO INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-03-19 09:09PM  Bragar Eagel & Squire, P.C. is Investigating Aptinyx, Inc. (NYSE: APTX) on Behalf of Aptinyx Stockholders and Encourages Aptinyx Investors to Contact the Firm Business Wire
01:45PM  IPO INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Oct-02-19 06:59PM  Shareholder Alert: Robbins Arroyo LLP is Investigating Aptinyx Inc. (APTX) on Behalf of Shareholders Business Wire
03:31AM  Aptinyx's Shares March Higher, Can It Continue? Zacks
Sep-30-19 07:03AM  Aptinyx to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-27-19 05:05PM  IPO SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Sep-26-19 03:15PM  IPO INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
08:07AM  Three Recent Preclinical Publications Highlight NMDA Receptor Activation Facilitated by Aptinyxs NYX-2925 GlobeNewswire
Sep-25-19 08:50AM  Is Aptinyx (NASDAQ:APTX) In A Good Position To Deliver On Growth Plans? Simply Wall St. -6.92%
Sep-24-19 09:00PM  IPO SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Sep-23-19 05:27PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm GlobeNewswire
Sep-20-19 03:35PM  IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Sep-16-19 05:06PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
Sep-13-19 02:00PM  ONGOING SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Sep-11-19 04:30PM  INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
08:40AM  Will Aptinyx Continue to Surge Higher? Zacks
Sep-09-19 06:35PM  IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Sep-07-19 02:58PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Sep-06-19 01:15PM  SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +6.40%
Sep-04-19 09:21PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Aptinyx Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
07:27AM  Former Principal Deputy Commissioner of FDA, Dr. Rachel Sherman, Joins Aptinyx Board of Directors GlobeNewswire
Aug-23-19 08:44AM  Zacks Market Edge Highlights: Google, Cisco, Aptinyx, Uber and Lyft Zacks
Aug-21-19 10:01PM  How Young Investors Find the Next Google Zacks
08:33AM  Aptinyx Presents Data Demonstrating Positive Activity of NYX-458 on Cognitive Performance and Biomarkers in a Preclinical Model of Head Injury GlobeNewswire
Aug-13-19 03:55PM  Aptinyx Represents Untapped Value, BMO Says Benzinga -11.29%
Aug-12-19 07:45AM  Aptinyx Inc. (APTX) Reports Q2 Loss, Lags Revenue Estimates Zacks
06:33AM  Aptinyx Reports Second Quarter 2019 Financial Results and Highlights GlobeNewswire
Aug-11-19 03:46PM  The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO Benzinga
Aug-08-19 11:05AM  Should You Take Comfort From Insider Transactions At Aptinyx Inc. (NASDAQ:APTX)? Simply Wall St.
Aug-06-19 08:33AM  Aptinyx to Present at the 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-05-19 08:03AM  Aptinyx to Report Second Quarter 2019 Financial Results on Monday, August 12, 2019 GlobeNewswire +7.94%
Jul-16-19 08:54AM  Aptinyx's Shares March Higher, Can It Continue? Zacks
Jul-12-19 08:30AM  Aptinyx Salutes Retiring Chief Scientific Officer and NMDA Receptor Drug Discovery Pioneer, Joseph Moskal GlobeNewswire
Jun-26-19 08:03AM  Aptinyx Presents Preclinical Data Demonstrating Robust Activity of NYX-783 on Alcohol-Seeking Behavior and Relapse-Like Behavior in Multiple Models of Alcohol Use Disorder GlobeNewswire
Jun-18-19 08:27AM  Aptinyx to Present at the 2019 BMO Prescription for Success Healthcare Conference GlobeNewswire +5.67%
Jun-10-19 07:23AM  Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain GlobeNewswire +14.90%
May-28-19 09:33AM  Could The Aptinyx Inc. (NASDAQ:APTX) Ownership Structure Tell Us Something Useful? Simply Wall St. -5.41%
May-14-19 06:27AM  Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
May-09-19 01:16PM  Were Hedge Funds Right About Dumping Aptinyx Inc. (APTX) ? Insider Monkey
May-07-19 07:23AM  Aptinyx Appoints Henry Gosebruch to Its Board of Directors GlobeNewswire
May-06-19 07:27AM  Aptinyx to Report First Quarter 2019 Financial Results on Tuesday, May 14, 2019 GlobeNewswire
May-02-19 06:00AM  Biotech Bets and a Goodbye from a Favorite Expert MoneyShow
Apr-30-19 07:27AM  Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers GlobeNewswire
Apr-18-19 07:27AM  Robust Analgesic Activity of Aptinyxs NYX-2925 in Advanced DPN Patients Revealed Through Further Analysis of Data from Phase 2 Study GlobeNewswire
Apr-04-19 08:00AM  Aptinyx to Present at 18th Annual Needham Healthcare Conference GlobeNewswire
Apr-03-19 07:27AM  Data in Parkinsons Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458 GlobeNewswire +6.83%
Mar-28-19 07:07AM  Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting GlobeNewswire
Mar-27-19 09:00AM  All You Need to Know About Aptinyx Inc. (APTX) Rating Upgrade to Buy Zacks
Mar-22-19 07:27AM  Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimers & Parkinsons Diseases GlobeNewswire +7.92%
Mar-21-19 07:07AM  Aptinyx Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress GlobeNewswire
Mar-14-19 08:00AM  Aptinyx to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, March 21, 2019 GlobeNewswire
Mar-06-19 08:00AM  Aptinyx to Present at Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-22-19 08:00AM  Aptinyx to Present at 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire +5.82%
Feb-19-19 07:27AM  Aptinyx Initiates Phase 2 Study to Evaluate Safety and Efficacy of NYX-783 in Patients with Post-Traumatic Stress Disorder GlobeNewswire
Jan-17-19 08:06AM  The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US Benzinga -9.87%
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sherman Rachel E.DirectorJan 22Buy4.792,17410,4132,174Jan 23 05:44 PM
Koppel AdamDirectorJan 14Buy3.003,333,3339,999,9995,558,425Jan 16 04:20 PM
ADAMS STREET PARTNERS LLC10% OwnerJan 10Buy3.001,000,0003,000,0001,465,716Jan 14 05:05 PM
RIEDEL NORBERT GCEO and PresidentJan 10Buy3.0035,000105,00035,000Jan 14 04:23 PM
HOMBACH ROBERT J.DirectorJan 10Buy3.0050,000150,000139,100Jan 14 04:21 PM
Gosebruch Henry ODirectorJan 10Buy3.0025,00075,000125,000Jan 14 04:19 PM
ENRIGHT PATRICK GDirectorJan 10Buy3.00166,667500,0013,356,746Jan 14 04:16 PM
ENRIGHT PATRICK GDirectorJan 10Buy3.0095,000285,00095,000Jan 14 04:16 PM
HOMBACH ROBERT J.DirectorNov 22Buy3.2450,000161,75089,100Nov 26 04:12 PM